Compare
Tevogen Inc. vs Eloxx Pharmaceuticals, Inc. vs AIM ImmunoTech Inc. vs Exozymes Inc.
| Latest fiscal year | Tevogen Inc. TVGN | Eloxx Pharmaceuticals, Inc. ELOX | AIM ImmunoTech Inc. AIM | Exozymes Inc. EXOZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $88.0K | n/a |
| Revenue growth (YoY) | n/a | -100.0% | -48.2% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$26.28M | -$6.00M | -$13.96M | -$9.16M |
| EPS (Diluted) | -$8.08 | -$0.49 | -$8.62 | -$1.09 |
| Operating cash flow | -$12.33M | -$6.33M | -$10.96M | -$6.50M |
| Free cash flow | -$12.39M | n/a | n/a | -$6.67M |
| Cash & equivalents | $0 | $4.79M | $2.98M | $3.04M |
| Total assets | $4.38M | $5.27M | $5.78M | $5.97M |
| Total liabilities | $12.62M | $17.18M | $15.56M | $2.57M |
| Shareholders' equity | -$8.23M | -$11.91M | -$9.78M | $3.40M |
| Return on year-end equity | n/a | n/a | n/a | -269.6% |
| Shares outstanding | 4.02M | 4.79M | 3.07M | 8.41M |
Revenue, most recent five fiscal years
| Fiscal year | Tevogen Inc. | Eloxx Pharmaceuticals, Inc. | AIM ImmunoTech Inc. | Exozymes Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $88.0K Ended 2025-12-31 | $70.1K Ended 2023-12-31 |
| 1 year earlier | n/a | $6.36M Ended 2024-12-31 | $170.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $202.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $141.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $135.0K Ended 2021-12-31 | n/a |